Imidacloprid + Permethrin

Verify with FDA CVM →

64 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
64
Total Reports
5
Deaths Reported
780.0%
Death Rate

Active Ingredients

ImidaclopridPermethrin

Administration Routes

TopicalUnknownOralOther

Species Affected

Dog 58
Cat 6

Most Affected Breeds

Domestic Shorthair 6
Chihuahua 5
Crossbred Canine/dog 5
Retriever - Labrador 3
Terrier - Yorkshire 3
Shepherd Dog - German 3
Shepherd Dog - Australian 3
Dog (unknown) 3
Spaniel - Cocker American 2
Mixed (Dog) 2

Most Reported Reactions

Vomiting 15
Lack of efficacy (ectoparasite) - flea 13
Seizure NOS 6
Behavioural disorder NOS 6
Pruritus 6
Diarrhoea 6
Muscle tremor 4
Lethargy (see also Central nervous system depression in 'Neurological') 4
Other abnormal test result NOS 4
Skin lesion NOS 3
Anorexia 3
Death by euthanasia 3

Outcome Breakdown

Outcome Unknown
31 (48.4%)
Recovered/Normal
16 (25.0%)
Ongoing
11 (17.2%)
Euthanized
3 (4.7%)
Died
2 (3.1%)
Recovered with Sequela
1 (1.6%)

Data Summary

Metric Value
Total adverse event reports 64
Reports involving death 5
Case-fatality rate (reported events) 780.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 2

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imidacloprid + Permethrin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 64 adverse event reports referencing Imidacloprid + Permethrin, including 5 reports in which the animal died — a 780.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Imidacloprid, Permethrin. Reported administration routes include Topical, Unknown, Oral, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imidacloprid + Permethrin reports are Dog (58 reports), Cat (6 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (6), Chihuahua (5), Crossbred Canine/dog (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imidacloprid + Permethrin are Vomiting (15), Lack of efficacy (ectoparasite) - flea (13), Seizure NOS (6), Behavioural disorder NOS (6). Of the 64 reports with a coded outcome, Outcome Unknown is the leading category at 48.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imidacloprid + Permethrin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial